| Primary information |
|---|
| ThPP ID | Th1073 |
| Therapeutic Peptide/Protein Name | Alemtuzumab |
| Sequence | Heavy Chain 1: QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMN view full sequnce in fasta |
| Functional Classification | IIa |
| Molecular Weight | 145453.8 |
| Chemical Formula | C6468H10066N1732O2005S40 |
| Isoelectric Point | 8.76 |
| Hydrophobicity | -0.431 |
| Melting Point (℃) | 61 (FAB f |
| Half Life | 288 hrs |
| Description | Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. |
| Indication/Disease | Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia. |
| Pharmacodynamics | Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations. |
| Mechanism of Action | Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells. |
| Toxicity | N.A. |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system when bound to B or T lymphocytes |
| Absorption | N.A. |
| Volume of Distribution | 0.18 L/kg |
| Clearance | N.A. |
| Categories | N.A. |
| Patents Number | CA1339198 |
| Date of Issue | 06/08/01 |
| Date of Expiry | 06/08/18 |
| Drug Interaction | Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. |
| Target | N.A. |
| Information of corresponding available drug in the market |
|---|
| Brand Name | CAMPATH |
| Company | Genzyme Corporation |
| Brand Discription | Campath (alemtuzumab) is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) directed against the 21-28 kD cell surface glycoprotein, CD52. Campath-1H is an IgG1 kappa antibody with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). The Campath-1H antibody has an approximate molecular weight of 150 kD. Campath is produced in mammalian cell (Chinese hamster ovary)Â |
| Prescribed for | Campath is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) |
| Chemical Name | N.A. |
| Formulation | Each single use vial of Campath contains 30 mg alemtuzumab, 8.0 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate. No preservatives are added. |
| Physcial Appearnce | Campath is a sterile, clear, colorless, isotonic solution (pH 6.8-7.4) for injection. |
| Route of Administration | Intravenous infusion |
| Recommended Dosage | Administer as an IV infusion over 2 hours, Escalate to recommended dose of 30 mg/day three times per week for 12 weeks, Premedicate with oral antihistamine and acetaminophen prior to dosing |
| Contraindication | None |
| Side Effects | Most common adverse reactions (>=10%): cytopenias, infusion reactions, cytomegalovirus (CMV) and other infections, nausea, emesis, diarrhea, and insomnia. |
| Useful Link | http://www.rxlist.com/campath-drug.htm |
| PubMed ID | 27645339, 26384035, 26253589, 25887773, 25846320, 24090587, 19967103, 16810345, 16179960, 18588450, 12130484, 17051245, 9593475 |
| 3-D Structure | Th1073 (View) or (Download) |